Efficacy and potential mechanism of atherosclerosis prevention by the active components of leech based on network pharmacology
Network pharmacology study published in Heliyon (2024)
Abstract
INTRODUCTION: Leeches are flesh-eating and bloodsucking parasitic worms. They are being used as a traditional Chinese medicine for centuries in activating blood and dissolving statis, dreging the meridims and tick. Hirudin, an active peptide product present in leech, has blood anticoagulant property and can assist in the treatment of thrombosis and diseases related to blood circulation. The efficacy and potential mechanism of action of leeches in such diseases should be further explored. MATERIALS AND METHODS: First, network pharmacology was used to screen the predicted potential targets of the active constituents of leech and AS. The common targets of the active constituents of leech and AS were obtained using Venn diagram. Further, the drug-active-constituent-target network diagram, protein-protein interaction, and GO and KEGG pathway enrichment analyses were used to construct the active-constituent-AS target-pathway network diagram. Subsequently, the protein-drug molecule docking model was drawn. Finally, the results of network pharmacology were validated using a mouse model of AS. RESULTS: In total, 34 active constituents of leech and 1172 AS-related gene targets were selected, took the drug action targets and potential disease targets to get the common targets, and took the top 10 of degree value as the main active constituents for the treatment of atherosclerosis. There were 89 common targets and 12 core targets. The main targets included MAPK, EGFR, PIK3CB, etc. Potential regulatory pathways included cancer pathways, EGFR tyrosine kinase inhibitor resistance, Rap1 signaling pathway, PPAR signaling pathway, PI3K-Akt signaling pathway, C-type lectin receptor signaling pathway, and AGE-RAGE signaling pathway in diabetic complications. Animal experiments using mouse model of AS confirmed that AS plaques were smaller after treatment with leeches. SRC level was measured using western blotting. Expression of SRC in myocardial tissue was remarkably lower in the mice treated with leech than in the mice from model group fed on high-fat chow. CONCLUSIONS: To the best of our knowledge, this is the first study to explore the mechanism of action of the active components of leech in AS prevention. The active components of leeches play a coordinated role in preventing AS through multicomponent, multitarget, and multichannel mechanism of action related to inflammatory response, oxidative stress, and lipid metabolism. This study provided a reference for subsequent cellular and animal experiments.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Network pharmacology combined with animal experiments showing leech extract's anti-atherosclerotic effects via PI3K/AKT, MAPK, and NF-κB pathway modulation.
Warum dies für die Hirudotherapie relevant ist
Diese Studie nutzte Netzwerk-Pharmakologie, um Zielstrukturen und Signalwege aktiver Substanzen des Blutegels bei Atherosklerose (AS) vorherzusagen, und validierte die Ergebnisse anschließend in einem Maus-AS-Modell, wobei nach Behandlung mit Blutegeln eine verringerte Plaquegröße und eine verminderte SRC-Expression im Myokardgewebe gezeigt wurden. Die Arbeit ist für das ASH-Fachgebiet relevant, da sie medizinisch wirksame Komponenten des gesamten Blutegels und deren anti-atherosklerotisches Potenzial über Multi-Target-Mechanismen untersucht, die Entzündungsreaktion, oxidativen Stress und Lipidstoffwechsel betreffen. Die Studie ist jedoch präklinisch (nur Mausmodell) und in ihrem Ansatz computergestützt plus tierexperimentell; sie isoliert keine spezifischen Sekretom-Komponenten und liefert keine klinischen Daten vom Menschen, und die genaue verwendete Blutegelzubereitung wird im Abstract nicht detailliert beschrieben. Die Relevanz ist daher indirekt und vorläufig.
Zitation
Efficacy and potential mechanism of atherosclerosis prevention by the active components of leech based on network pharmacology.
Lv Q et al. · Heliyon, 2024
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026